Patents Assigned to Eli Lilly & Company
  • Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
    Patent number: 7582638
    Abstract: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Alfonso De Dios, Cristina Garcia-Paredes, Beatriz López de Uralde Garmendia, Mary Margaret Mader, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Salt and crystalline forms of (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-YL)piperazin-1-YL]-2-hydroxypropoxy}quinoline
    Patent number: 7582762
    Abstract: The present invention provides methods of treating leukemia comprising administration of a resistance modulating amount of a compound having the formula (2r)-anti-5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline 2.5 hydrochloride.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Julie Kay Bush, Susan Marie Reutzel-Edens
  • Vitamin D receptor modulators
    Patent number: 7582775
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
  • Muteins of fibroblast growth factor 21
    Patent number: 7582607
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
  • Selective VPAC2 receptor peptide agonists
    Patent number: 7582608
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Kinase inhibitors
    Patent number: 7582652
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Chafiq Hamdouchi, Chuan Shih, Alfonso De Dios, Miriam Filadelfa del Prado, Carlos Jaramillo Aguado, Pramila Kotiyan, Mary Margaret Mader, Sheila Pleite Selgas, Concepcion Sanchez-Martinez
  • Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
    Publication number: 20090214598
    Abstract: The present invention provides a pro-inflammatory synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which a first epitope and a second epitope are each covalently attached. The first epitope comprises one or more than one generic T helper peptide sequence, and the second epitope comprises one or more than one target epitope. The first and second epitopes are present in one or more copies each within the SPA. Each target epitope is a peptide sequence or a carbohydrate moiety, and is an immunogen to CD8+ T cells or B cells. The present invention also provides a suppressive synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which one or more than one target epitope is covalently attached.
    Type: Application
    Filed: April 19, 2006
    Publication date: August 27, 2009
    Applicant: Eli Lilly and Company
    Inventor: Larry Chris Blaszczak
  • Vitamin D receptor modulators
    Patent number: 7579488
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: August 25, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jianliang Lu, Tianwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Jason Matthew Ochoada, Ying Kwong Yee
  • FGF-21 fusion proteins
    Patent number: 7576190
    Abstract: The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: August 18, 2009
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Yu Tian, Sheng-Hung Rainbow Tschang
  • Substituted arylcyclopropylacetamides as glucokinase activators
    Patent number: 7576108
    Abstract: According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: August 18, 2009
    Assignee: Eli Lilly and Company
    Inventors: Andreas Gerhard Weichert, David Gene Barrett, Stefan Heuser, Rainer Riedl, Mark Joseph Tebbe, Andrea Zaliani
  • Spiro derivatives as lipoxygenase inhibitors
    Patent number: 7576094
    Abstract: The present invention is concerned with certain novel spiro substituted heterocylic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of pharmaceutical formulations for the treatment of lipoxygenase-mediated disorders.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: August 18, 2009
    Assignee: Eli Lilly and Company
    Inventors: Daniel T. W. Chu, Jian Chen, Wei Zhang, Xianfeng Li, Jiangao Song, Bing Wang, Qiang Cong, Donald R. James
  • Vitamin D receptor modulators
    Patent number: 7566803
    Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: July 28, 2009
    Assignee: Eli Lilly and Company
    Inventor: Jianliang Lu
  • Diaryl ethers as opioid receptor antagonists
    Patent number: 7560463
    Abstract: Compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, useful for the treatment of irritable bowel syndrome.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: July 14, 2009
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Michael Angelo Statnick
  • Pseudomycin production by pseudomonas syringae
    Patent number: 7556960
    Abstract: A method for producing one or more pseudomycins is described including cultures of Pseudomonas syringae that produce one or more pseudomycins having general formula (I) where R is a lipophilic moiety.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: July 7, 2009
    Assignee: Eli Lilly and Company
    Inventors: Matthew Dale Hilton, Robert Joseph Strobel, Jr., Penelope Jane Beverly Millar, Dennis Nelson Thomas, Andrew Richard Cockshott, Brian Gerald Getman, Jack Richard Eastridge, Cathleen Alice Cantwell
  • Polyethylene glycol linked GLP-1 compounds
    Patent number: 7557183
    Abstract: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: July 7, 2009
    Assignee: Eli Lilly and Company
    Inventors: Richard Dennis DiMarchi, Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
  • Imidazopyridazine compounds
    Patent number: 7557103
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: July 7, 2009
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Aaron Collins, Pablo Garcia-Losada, Chafiq Hamdouchi, Philip Arthur Hipskind, Jianliang Lu, Takako Takakuwa
  • Echinocandin/carbohydrate complexes
    Patent number: 7550428
    Abstract: A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: June 23, 2009
    Assignee: Eli Lilly and Company
    Inventors: Larry A. Larew, Nathaniel Milton, James Lawrence Sabatowski, Kenneth Philip Moder
  • Stabilized teriparatide solutions
    Patent number: 7550434
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: June 23, 2009
    Assignee: Eli Lilly and Company
    Inventors: Chin-Ming Chang, Henry A. Havel
  • [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases
    Patent number: 7547691
    Abstract: The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: June 16, 2009
    Assignee: Eli Lilly and Company
    Inventors: Karl Robert Dahnke, Ho-Shen Lin, Michael Enrico Richett, Chuan Shih, Q May Wang, Bo Zhang
  • Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
    Patent number: RE40876
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: August 18, 2009
    Assignee: Eli Lilly and Company
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, Louis Vignati, William Terry Johnson